4.6 Editorial Material

Is bronchopulmonary dysplasia in adult age a novel COPD endotype?

期刊

EUROPEAN RESPIRATORY JOURNAL
卷 60, 期 3, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.00984-2022

关键词

-

资金

  1. Chiesi
  2. AstraZeneca
  3. GSK
  4. BI
  5. Pfizer
  6. Teva
  7. Sanofi
  8. Novartis
  9. Iqvia
  10. Avillion
  11. ElpenPharmaceuticals
  12. Exobiologics

向作者/读者索取更多资源

Bronchopulmonary dysplasia is a chronic respiratory disease characterized by inflammation, starting in childhood and possibly continuing into adulthood.
Bronchopulmonary dysplasia is a chronic respiratory disease involving inflammation that occurs in childhood and may continue into adult age. BPD can be considered the earliest and longest lasting obstructive lung disease in humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据